SCHEMBL8021772

SCHEMBL8021772

Cc1ncnc2ccc(Br)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 9/20 0.57
LMNA P02545 6/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
ALDH1A1 P00352 4/20 0.56
CCNC P24863 1/20 0.54
CDK8 P49336 1/20 0.54
MAPK1 P28482 1/20 0.53
MAPT P10636 1/20 0.50
NCOA1 Q15788 2/20 0.49
NCOA3 Q9Y6Q9 2/20 0.49
NPC1 O15118 1/20 0.49
KDM4E B2RXH2 2/20 0.49
ALK Q9UM73 1/20 0.49
HPGD P15428 1/20 0.49
MTOR P42345 1/20 0.49
MEN1 O00255 1/20 0.49
GLA P06280 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PIK3CD O00329 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21569367 0.87 HTT (0.53) HTTLMNASMN1; SMN2ALDH1A1CCNC
SCHEMBL31469313 0.84 MPO (0.45) HTTLMNASMN1; SMN2ALDH1A1CCNC
SCHEMBL6956273 0.79 HTT (0.53) HTTLMNASMN1; SMN2ALDH1A1MAPK1
SCHEMBL2622072 0.77 HTT (0.68) HTTLMNASMN1; SMN2ALDH1A1CCNC
SCHEMBL934881 0.76 LMNA (0.58) HTTLMNASMN1; SMN2ALDH1A1CCNC
SCHEMBL182875 0.76 LMNA (0.57) HTTLMNASMN1; SMN2ALDH1A1CCNC
SCHEMBL3106281 0.76 HTT (0.53) HTTLMNASMN1; SMN2ALDH1A1CCNC
SCHEMBL13043853 0.76 USP10 (0.49) HTTLMNAHIF1A
SCHEMBL2508850 0.76 MAP4K4 (0.56) HTTLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL12844378 0.76 CSF1R (0.51) HTTLMNAALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113166119-B Substituted aryl compound and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-01-05 CN disclosed
CN-111377873-B Aminopyrimidine compounds, their preparation and use 四川科伦博泰生物医药股份有限公司 2023-03-28 CN disclosed
CN-110684020-B 2-aminopyrimidine derivatives, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-01-20 CN disclosed
CN-111377906-B Substituted pyrazine compounds, their preparation and use 四川科伦博泰生物医药股份有限公司 2022-09-02 CN disclosed
CN-111094254-B Heteroaryl derivative, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2022-07-26 CN disclosed
EP-3567030-B1 QUINAZOLINE COMPOUND FOR EGFR INHIBITION MEDSHINE DISCOVERY INC (CN) 2022-02-09 EP disclosed
US-20210395226-A1 SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2021-12-23 US disclosed
EP-3904352-A1 SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2021-11-03 EP disclosed
EP-3904352-A1 SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2021-11-03 EP disclosed
CN-113166119-A Substituted aryl compound and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2021-07-23 CN disclosed
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-03-31 US disclosed
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-03-31 US disclosed
WO-2009114870-A2 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 WO disclosed
EP-2098508-A1 Cyclic derivatives as modulators of chemokine receptor activity Bristol-Myers Squibb Company (US) 2009-09-09 EP disclosed
US-20080114052-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-05-15 US disclosed
US-20080114052-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-05-15 US disclosed
US-7338947-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB CO. (US) 2008-03-04 US disclosed
US-7183270-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-27 US disclosed
US-7183270-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-27 US disclosed
US-20070032541-A1 Cyclic derivatives as modulators of chemokine receptor activity CHERNEY ROBERT J 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114052-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCL11, CCL2, CCR1 HTT 4484/4885LMNA 4039/4885SMN1; SMN2 3923/4885
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE MAP3K20, MAP3K1, PDPK1 HTT 3239/4885LMNA 2831/4885SMN1; SMN2 4472/4885
US-20070032541-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCL2, CCR1 HTT 4484/4885LMNA 4039/4885SMN1; SMN2 3923/4885
US-20210395226-A1 SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF ADORA2A, ADORA1, ADORA3 HTT 2686/4885LMNA 1702/4885SMN1; SMN2 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.